In vitro analysis of liver steatosis using adverse outcome pathways: A case study with cyproconazole
C. Luckert
(1)
,
A. Braeuning
(1)
,
Georges de Sousa
(2)
,
S. Durinck
(3)
,
E. S. Katsanou
(4)
,
P. Konstantinidou
(4)
,
K. Machera
(4)
,
E. S. Milani
(5)
,
A. Peijnenburg
(6)
,
Roger Rahmani
(2)
,
A. Rajkovic
(3)
,
A. Spyropoulou
(4)
,
M. Stamou
(5)
,
G. Stoopen
(6)
,
Sj. Sturla
(5)
,
Nathalie Zucchini-Pascal
(2)
,
A. Lampen
(1)
1
BfR -
Bundesinstitut für Risikobewertung - Federal Institute for Risk Assessment
2 ToxAlim - ToxAlim
3 UGENT - Universiteit Gent = Ghent University
4 BPI - Benaki Phytopathological Institute
5 ETH Zürich - Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich]
6 RIKILT
2 ToxAlim - ToxAlim
3 UGENT - Universiteit Gent = Ghent University
4 BPI - Benaki Phytopathological Institute
5 ETH Zürich - Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich]
6 RIKILT